The VAXEF study held a training on the 16th of February on the updated study protocol and introduced 2 new sub-studies which will be starting in the next few months. The first sub-study is aiming to evaluate point-of-care diagnostic tools for diabetes in routine outpatient care. They are going to compare 2 point of care HbA1c assays to a laboratory HbA1c, random and fasting glucose, and the gold standard oral glucose tolerance test in order to understand the limitations of current diagnostic strategies, and how best we might make an accurate diagnosis of diabetes more widely available. The second sub-study, in collaboration with Zvitambo and University of Sheffield, will evaluate immune responses among people who have and have not received COVID vaccines, and people with COVID-19 infection.
top of page
bottom of page